Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Ophthalmology
RheumMadness
RheumMadness
Questions discussed in this category
How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?
This question is part of a collaboration with RheumMadness and is specifically in reference to: Cost Effectiveness of HCQ Screening.
3 Answers available
22715
Papers discussed in this category
Arthritis & rheumatology (Hoboken, N.J.), 2021 Apr 26
American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity.
Ophthalmology, 2016-06
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Related Topics in Ophthalmology
Rheumatology
Uveitis and Ocular Immunology
General Internal Medicine
Neuro-Ophthalmology
Neurology
Inflammatory eye disorders
Vitreoretinal Diseases and Surgery
Cornea and External Disease
General Rheumatology
Radiation Oncology